Long-Term Safety of Ubrogepant for the Treatment of Migraine Long-Term Safety of Ubrogepant for the Treatment of Migraine

This study evaluated the safety and tolerability of intermittent treatment over the course of 1 year with ubrogepant, a calcitonin gene-related peptide, for the acute treatment of migraine.Headache

Source: Medscape Today Headlines - February 11, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news